Page 1061 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

8 References

211. Giamarellou H, Bassaris HP, Petrikkos G, et al. Monotherapy 226. Kern WV, Andriof E, Oethinger M, Kern P, Hacker J, Marre R.
with intravenous followed by oral high-dose ciprofloxacin Emergence of fluoroquinolone-resistant Escherichia coli at a can-
versus combination therapy with ceftazidime plus amikacin as cer center. Antimicrob Agents Chemother. 1994;38(4):681-687.
initial empiric therapy for granulocytopenic patients with fever. 227. Carratala J, Fernandez-Sevilla A, Tubau F, Callis M, Gudiol F.
Antimicrob Agents Chemother. 2000;44(12):3264-3271. Emergence of quinolone-resistant Escherichia coli bacteremia
212. Studena M, Hlavacova E, Helpianska L, et al. Once-daily in neutropenic patients with cancer who have received prophy-
pefloxacin + teicoplanin vs netilmicin + teicoplanin in lactic norfloxacin. Clin Infect Dis. 1995;20(3):557-560.
empirical therapy for fever and neutropenia. Drugs. 1995;49 228. Zaidi Y, Hastings M, Murray J, Hassan R, Kurshid M, Mahendra P.
(suppl 2):483-485. Quinolone resistance in neutropenic patients: the effect of
213. Cornely OA, Wicke T, Seifert H, et al. Once-daily oral levofloxa- prescribing policy in the UK and Pakistan. Clin Lab Haematol.
cin monotherapy versus piperacillin/tazobactam three times a 2001;23(1):39-42.
day: a randomized controlled multicenter trial in patients with 229. Cattaneo C, Quaresmini G, Casari S, et al. Recent changes in
febrile neutropenia. Int J Hematol. 2004;79(1):74-78. bacterial epidemiology and the emergence of fluoroquino-
214. Chamilos G, Bamias A, Efstathiou E, et al. Outpatient treat- lone-resistant Escherichia coli among patients with haema-
ment of low-risk neutropenic fever in cancer patients using oral tological malignancies: results of a prospective study on 823
moxifloxacin. Cancer. 2005;103(12):2629-2635. patients at a single institution. J Antimicrob Chemother. March
215. Sebban C, Dussart S, Fuhrmann C, et al. Oral moxifloxacin or 2008;61(3):721-728.
intravenous ceftriaxone for the treatment of low-risk neutrope- 230. Pena C, Albareda JM, Pallares R, Pujol M, Tubau F, Ariza J.
nic fever in cancer patients suitable for early hospital discharge. Relationship between quinolone use and emergence of cipro-
Support Care Cancer. 2008;16:1017-1023. floxacin-resistant Escherichia coli in bloodstream infections.
216. Horowitz HW, Holmgren D, Seiter K. Stepdown single agent Antimicrob Agents Chemother. 1995;39(2):520-524.
antibiotic therapy for the management of the high risk neutro- 231. Farra A, Skoog G, Wallen L, Kahlmeter G, Kronvall G, Sorberg
penic adult with hematologic malignancies. Leuk Lymphoma. M. Antibiotic use and Escherichia coli resistance trends for
1996;23:159-163. quinolones and cotrimoxazole in Sweden. Scand J Infect Dis.
217. Marra CA, Frighetto L, Quaia CB, et al. A new ciprofloxacin 2002;34(6):449-455.
stepdown program in the treatment of high-risk febrile neu- 232. Garau J, Xercavins M, Rodriguez-Carballeira M, et al. Emergence
tropenia: a clinical and economic analysis. Pharmacotherapy. and dissemination of quinolone-resistant Escherichia
2000;20(8):931-940. coli in the community. Antimicrob Agents Chemother.
218. Kern WV, Cometta A, De BR, Langenaeken J, Paesmans M, 1999;43(11):2736-2741.
Gaya H. Oral versus intravenous empirical antimicrobial ther- 233. Perea S, Hidalgo M, Arcediano A, et al. Incidence and clini-
apy for fever in patients with granulocytopenia who are receiv- cal impact of fluoroquinolone-resistant Escherichia coli in the
ing cancer chemotherapy. International Antimicrobial Therapy faecal flora of cancer patients treated with high dose chemo-
Cooperative Group of the European Organization for Research therapy and ciprofloxacin prophylaxis. J Antimicrob Chemother.
and Treatment of Cancer. N Engl J Med. 1999;341(5):312-318. 1999;44(1):117-120.
219. Freifeld A, Marchigiani D, Walsh T, et al. A double-blind com- 234. Gomez L, Garau J, Estrada C, et al. Ciprofloxacin prophylaxis in
parison of empirical oral and intravenous antibiotic therapy patients with acute leukemia and granulocytopenia in an area
for low-risk febrile patients with neutropenia during cancer with a high prevalence of ciprofloxacin-resistant Escherichia
chemotherapy. N Engl J Med. 1999;341(5):305-311. coli. Cancer. 2003;97(2):419-424.
220. Niho S, Ohe Y, Goto K, et al. Randomized trial of oral versus 235. Lautenbach E, Larosa LA, Kasbekar N, Peng HP, Maniglia RJ,
intravenous antibiotics in low-risk febrile neutropenic patients Fishman NO. Fluoroquinolone utilization in the emer-
with lung cancer. Jpn J Clin Oncol. 2004;34(2):69-73. gency departments of academic medical centers: prevalence
221. Paganini H, Rodriguez-Brieshcke T, Zubizarreta P, et al. of, and risk factors for, inappropriate use. Arch Intern Med.
Oral ciprofloxacin in the management of children with can- 2003;163(5):601-605.
cer with lower risk febrile neutropenia. Cancer. April 15, 236. Lautenbach E, Strom BL, Bilker WB, Patel JB, Edelstein PH,
2001;91(8):1563-1567. Fishman NO. Epidemiological investigation of fluoroqui-
222. Mullen CA. Ciprofloxacin in treatment of fever and neu- nolone resistance in infections due to extended-spectrum
tropenia in pediatric cancer patients. Pediatr Infect Dis J. beta- lactamase-producing Escherichia coli and Klebsiella pneu-
2003;22(12):1138-1142. moniae. Clin Infect Dis. 2001;33(8):1288-1294.
223. Freifeld A, Sankaranarayanan J, Ullrich F, Sun J. Clinical prac- 237. Fainstein V. New antimicrobial agents in the immunocompro-
tice patterns of managing low-risk adult febrile neutropenia mised cancer patient. Int J Microbiol Hyg. 1985:191-198.
during cancer chemotherapy in the USA. Support Care Cancer. 238. Furno P, Dionisi MS, Bucaneve G, Menichetti F, Del Favero A.
2008;16(2):181-191. Ceftriaxone versus beta-lactams with antipseudomonal activity
224. Freifeld AG, Segal BH, Baden LR, et al. Prevention and for empirical, combined antibiotic therapy in febrile neu-
treatment of cancer-related infections. 2007. http://www.nccn tropenia: a meta-analysis. Support Care Cancer. 2000;8(4):
.org/professionals/physician_gls/PDF/infections.pdf. Accessed 293-301.
August 6, 2007. 239. Bow EJ, Noskin GA, Schwarer AP, Laverdiere M, Vesole DH.
225. Cometta A, Calandra T, Bille J, Glauser MP. Escherichia coli Efficacy of Piperacillin/Tazobactam as initial empiric therapy
resistant to fluoroquinolones in patients with cancer and neu- for febrile neutropenia in patients with hematological malig-
tropenia. N Engl J Med. 1994;330(17):1240-1241. nancy. Blood. 2003;102(11):281a. (Abstract #1000).

Section05-O-ref.indd 8 1/20/2015 4:51:20 PM